Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-15-2290
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

RIPK3 Expression as a Potential Predictive and Prognostic Marker in Metastatic Colon Cancer

Clinical and Investigative Medicine
Medicine
2019English

Prospective Evaluation of a 12-Gene Assay on Patient Treatment Decisions and Physician Confidence in Mismatch Repair Proficient Stage IIA Colon Cancer

Clinical Colorectal Cancer
OncologyGastroenterology
2017English

Characteristics of BRAFV600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients

Oncologist
Cancer ResearchMedicineOncology
2019English

L1TD1 - A Prognostic Marker for Colon Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Expression of Aquaporin-1 Is a Poor Prognostic Factor for Stage II and III Colon Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2013English

Identification of a Sixteen-microRNA Signature as Prognostic Biomarker for Stage II and III Colon Cancer

Oncotarget
Oncology
2017English

Prognostic and Predictive Role of DNA Mismatch Repair Status in Stage II‐III Colorectal Cancer: A Systematic Review and Meta‐Analysis

Clinical Genetics
Genetics
2019English

P53 Expression as a Prognostic Marker in Inflammatory Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2004English

Prognostic Impact of Mutation Profiling in Patients With Stage II and III Colon Cancer

Scientific Reports
Multidisciplinary
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy